Introduction
============

Pulmonary squamous cell carcinomas, for which incidence rates are on the decline in Japan possibly owing to declining trends in smoking prevalence, still account for 35% and 16% of Japanese cases in men and women, respectively.[@b1-lctt-7-099] Over the last decade, some promising antitumor drugs and personalized therapies based on genetic information have been developed for non-squamous non-small-cell lung cancer (NSCLC). In contrast, squamous cell carcinoma has been left behind in terms of new chemotherapies and treatments. Today, treatment strategies differ markedly between squamous and non-squamous NSCLCs.

For patients with advanced NSCLC, chemotherapy is still a standard treatment option. However, except for patients with NSCLC harboring specific gene mutations, older patients, and patients with poor performance status (PS), platinum-based combination regimens are recommended as the standard first-line treatment for advanced NSCLC. However, almost all patients experience progression during or after first-line chemotherapy, and some of them require salvage chemotherapy. Some single- and multi-institutional and database-based survey studies have reported that patients with advanced NSCLC have received best supportive care (BSC) alone, or first- and later-line chemotherapy. With the exception of a study based on data from the US Medicare database,[@b2-lctt-7-099] there is no other study that has focused on patients with squamous cell carcinoma and followed their course of chemotherapy.

Our retrospective study focused on squamous cell carcinoma and aimed to investigate 1) the percentage of patients treated with first-, second-, or third-line chemotherapy and 2) the types of patients for whom chemotherapy had been beneficial.

Methods
=======

Patients and study design
-------------------------

This study was a single-institution retrospective study performed at the Osaka Police Hospital. First, to investigate predictive markers distinguishing the chemotherapy group from the non-chemotherapy group, we extracted data on patients who were histologically or cytologically diagnosed with stage IIIB or IV pulmonary squamous cell carcinomas between June 2007 and March 2015. We excluded patients who had transferred to other hospitals to receive aggressive treatment, and patients with squamous cell carcinomas combined with other histological types. We compared patients who were treated with chemotherapy (chemotherapy group) with patients who were not treated with chemotherapy (non-chemotherapy group). Second, to investigate prognostic markers of each line of chemotherapy, we retrospectively abstracted three cohorts of patients who had initiated first-, second-, or third-line chemotherapy between June 2007 and November 2015 at our hospital. We excluded patients who had received front-line chemotherapy at another hospital and then transferred to our hospital and received later-line chemotherapy.

Extraction of data, criteria for the evaluable population for overall response rate (RR), and definitions of overall RR, overall survival (OS), and progression-free survival (PFS) were as previously described.[@b3-lctt-7-099] Laboratory data obtained from venous samples included absolute leukocyte count, neutrophil count, lymphocyte count, monocyte count, hemoglobin level, red cell distribution width (RDW) coefficient of variation (measured using a method that shows heterogeneity in erythrocyte size, which has been recently reported to be associated with cancer survival[@b4-lctt-7-099]), platelet count, serum sodium concentration, and lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and C-reactive protein (CRP) levels. These laboratory data were obtained on the last day within 1 month before the examination that confirmed the diagnosis of malignancy, or on the last day within 1 week before the first day of each chemotherapy treatment. The cutoff date was November 31, 2015. The Osaka Police Hospital Ethics Committee approved this study (number 501) and waived the requirement for informed consent.

Data analysis
-------------

The data for normally distributed continuous variables, discrete variables, and categorical variables are expressed as the mean ± standard deviation or median (range) and frequency.

The chemotherapy and non-chemotherapy groups were compared using Fisher's exact test, Mann--Whitney *U* test, and unpaired *t*-test for relative frequencies, discrete variables, and normally distributed continuous variables, respectively. All variables with a *P*-value \<0.1 were included in the univariate analysis. Continuous and laboratory variables were divided using optimal cutoff values, which were decided using receiver operating characteristic curve analysis. The cutoff values were evaluated using the area under the curve and defined as the value corresponding to the maximum joint sensitivity and specificity on the receiver operating characteristic plot. Age, Eastern Cooperative Oncology Group (ECOG)-PS, and body mass index (BMI) were arbitrarily divided using the following cutoff points: 75 years of age, PS 2, and BMI 18.5 kg/m^2^. Univariate analysis was used to select backgrounds and laboratory data with a *P*-value \<0.1 at diagnosis which were likely to have influenced whether or not to introduce chemotherapy. The subsequent multivariate logistic regression analysis used those variables selected in the univariate analysis. The results are expressed by an odds ratio (OR) and a confidence interval (CI) of 95%.

Univariate and multivariate Cox proportional hazards analyses examined which backgrounds and laboratory data at the start of chemotherapy had influenced OS after each line of chemotherapy. Univariate analysis was used to select for variables with a *P*-value \<0.1, and the subsequent multivariate analysis was performed using those variables. The results are shown in terms of the hazard ratio (HR) and 95% CI.

To evaluate relationships between various laboratory data, Pearson's correlation coefficient was used. We considered a *P*-value \<0.05 as significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics.[@b5-lctt-7-099]

Results
=======

Between June 2007 and March 2015, 154 patients were diagnosed with stage IIIB or IV squamous cell carcinomas at our hospital. Among them, 103 patients received chemotherapy, and 51 did not ([Figure S1](#SD1-lctt-7-099){ref-type="supplementary-material"}).

First, we compared the chemotherapy group with the non-chemotherapy group. The chemotherapy group comprised significantly younger patients (69.4±8.2 vs 77.5±7.5 years, *P*\<0.01), included a higher proportion of males (*P*=0.04), had a better PS (*P*\<0.01), had a lower Charlson comorbidity index (1.1±1.0 vs 1.7±1.5, *P*=0.01), and survived longer (median 361 vs 80 days, *P*\<0.01) ([Table 1](#t1-lctt-7-099){ref-type="table"}). Regarding laboratory data, absolute lymphocyte count (1,803±697 vs 1,478±566 cells/μL, *P*\<0.01), hemoglobin (13.0±1.7 vs 11.8±1.5 g/dL, *P*\<0.01), and serum sodium concentration (139.6±3.0 vs 137.8±3.8 mEq/L, *P*\<0.01) were significantly higher, while RDW (13.5%±0.9% vs 14.1%±1.2%, *P*\<0.01) was lower in the chemotherapy group than in the non-chemotherapy group ([Table S1](#SD2-lctt-7-099){ref-type="supplementary-material"}). The optimal cutoff values are shown in [Table S2](#SD3-lctt-7-099){ref-type="supplementary-material"}. Factors predicting unlikely chemotherapy, determined using univariate analysis, included the following eight factors: age ≥75 years (OR 0.23, 95% CI 0.10--0.49, *P*\<0.01), female sex (OR 0.43, 95% CI 0.18--0.99, *P*=0.04), ECOG-PS 2--4 (OR 0.16, 95% CI 0.07--0.35, *P*\<0.01), Charlson comorbidity index ≥2 (OR 0.29, 95% CI 0.11--0.73, *P*\<0.01), lymphocyte count \<1,710 cells/μL (OR 0.33, 95% CI 0.14--0.73, *P*\<0.01), hemoglobin \<12.2 g/dL (OR 0.23, 95% CI 0.10--0.49, *P*\<0.01), RDW ≥13.9% (OR 0.30, 95% CI 0.14--0.64, *P*\<0.01), and serum sodium \<140 mEq/L (OR 0.27, 95% CI 0.12--0.59, *P*\<0.01). However, multivariate logistic regression analysis was used to determine the following five factors: age ≥75 years (OR 0.23, 95% CI 0.09--0.61, *P*\<0.01), ECOG-PS 2--4 (OR 0.18, 95% CI 0.07--0.48, *P*\<0.01), Charlson comorbidity index ≥2 (OR 0.19, 95% CI 0.06--0.61, *P*\<0.01), hemoglobin \<12.2 g/dL (OR 0.36, 95% CI 0.14--0.96, *P*=0.04), RDW ≥13.9% (OR 0.26, 95% CI 0.09--0.72, *P*\<0.01), and serum sodium \<140 mEq/L (OR 0.23, 95% CI 0.09--0.62, *P*\<0.01) ([Table 2](#t2-lctt-7-099){ref-type="table"}).

Second, we followed patients who received chemotherapy and investigated prognostic markers for each line of chemotherapy. Between June 2007 and November 2015, 103, 63, and 32 patients received first-, second-, and third-line chemotherapy, respectively ([Figure S1](#SD1-lctt-7-099){ref-type="supplementary-material"}). [Tables 3](#t3-lctt-7-099){ref-type="table"} and [S3](#SD4-lctt-7-099){ref-type="supplementary-material"} show patient characteristics and laboratory data before receiving first-, second-, and third-line chemotherapy, respectively. Carboplatin plus paclitaxel, docetaxel monotherapy, and the combination of gemcitabine and vinorelbine were most frequently adopted in first-, second-, and third-line chemotherapy settings, respectively ([Table S4](#SD5-lctt-7-099){ref-type="supplementary-material"}). The most frequent reason of discontinuation was documented progressive disease in patients treated with any line. PFS, RR, and disease control rate (DCR) decreased from first- to third-line ([Tables 3](#t3-lctt-7-099){ref-type="table"} and [S5](#SD6-lctt-7-099){ref-type="supplementary-material"}). Univariate Cox hazard analysis was used to determine that the following variables were factors predicting OS from the start of each line of chemotherapy: ECOG-PS (HR 2.50, 95% CI 1.52--4.12, *P*\<0.01), neutrophil count (HR 1.11, 95% CI 1.02--1.20, *P*=0.01), lymphocyte count (HR 0.61, 95% CI 0.40--0.92, *P*=0.02), monocyte count (HR 1.18, 95% CI 1.06--1.32, *P*\<0.01), platelet count (HR 1.23, 95% CI 1.01--1.61, *P*=0.04), ALP (HR 1.41, 95% CI 1.10--1.81, *P*\<0.01), and CRP (HR 1.11, 95% CI 1.05--1.17, *P*\<0.01) in first-line ([Table 4](#t4-lctt-7-099){ref-type="table"}); ECOG-PS (HR 3.11, 95% CI 1.66--5.83, *P*\<0.01), stage (HR 2.04, 95% CI 1.07--3.89, *P*=0.03), neutrophil count (HR 1.11, 95% CI 1.03--1.19, *P*\<0.01), lymphocyte count (HR 0.49, 95% CI 0.29--0.85, *P*=0.01), hemoglobin (HR 0.76, 95% CI 0.65--0.89, *P*\<0.01), RDW (HR 1.34, 95% CI 1.15--1.62, *P*\<0.01), serum sodium concentration (HR 0.89, 95% CI 0.82--0.98, *P*=0.01), LDH (HR 1.10, 95% CI 1.01--1.19, *P*=0.03), ALP (HR 1.18, 95% CI 1.02--1.36, *P*=0.02), CRP (HR 1.11, 95% CI 1.03--1.18, *P*\<0.01), and the interval between first- and second-line (HR 0.88, 95% CI 0.80--0.95, *P*\<0.01) in second-line ([Table 5](#t5-lctt-7-099){ref-type="table"}); and ECOG-PS (HR 4.86, 95% CI 1.84--12.8, *P*\<0.01) and RDW (HR 1.31, 95% CI 1.03--1.67, *P*=0.03) in third-line ([Table 6](#t6-lctt-7-099){ref-type="table"}). Multivariate Cox hazard analysis was also used to determine that the following variables were factors predicting OS from the start of each line of chemotherapy: ECOG-PS (HR 2.54, 95% CI 1.46--4.42, *P*\<0.01) in first-line ([Table 4](#t4-lctt-7-099){ref-type="table"}); ECOG-PS (HR 2.12, 95% CI 1.02--4.41, *P*=0.04) and lymphocyte count (HR 0.45, 95% CI 0.22--0.92, *P*=0.03) in second-line ([Table 5](#t5-lctt-7-099){ref-type="table"}); and ECOG-PS (HR 9.48, 95% CI 2.68--33.6, *P*\<0.01), BMI (HR 4.89, 95% CI 1.61--14.9, *P*\<0.01), hemoglobin (HR 0.70, 95% CI 0.51--0.95, *P*=0.02), and LDH (HR 2.79, 95% CI 1.22--6.38, *P*=0.01) in third-line ([Table 6](#t6-lctt-7-099){ref-type="table"}).

Discussion
==========

This retrospective study reported on the course of chemotherapy for unselected patients with squamous cell carcinomas, and determined several predictive markers affecting commencement of chemotherapy and survival benefits from first-, second-, and third-line chemotherapy. This is the first study that observed longitudinally the chemotherapeutic course of patients with advanced squamous cell carcinomas.

Our study revealed a trend in patients with advanced squamous cell carcinomas. First, in our study, among patients who had been diagnosed with advanced squamous cell carcinomas, 67% received chemotherapy. Similarly, 71.4% of patients with metastatic NSCLC at a German university hospital were treated with chemotherapy,[@b6-lctt-7-099] which was higher than the 45% of patients aged ≥65 years with metastatic squamous NSCLC treated with chemotherapy in a US study[@b2-lctt-7-099] but lower than the 86% of patients with stage IIIB, IV, or postsurgical recurrence treated with chemotherapy at a Japanese cancer center,[@b7-lctt-7-099] or the 91.4% of patients with stage IIIB or IV NSCLC treated with chemotherapy in an Italian multicenter survey study.[@b8-lctt-7-099] Second, among all patients who had received first-line chemotherapy (in which six and two patients were excluded because they did not experience progression after first- and second-line chemotherapy, respectively), 65% and 34% received second-and third-line chemotherapy, respectively. The proportion of patients who received second- and third-line chemotherapy was consistent with those in previous studies, most of which investigated patients with NSCLC, regardless of histological type ([Table 7](#t7-lctt-7-099){ref-type="table"}).[@b2-lctt-7-099],[@b6-lctt-7-099]--[@b16-lctt-7-099] Thus, although receipt of first-line chemotherapy varied, the percentage of patients who had received second- and third-line chemotherapy was nearly the same, irrespective of country or institution.

We identified prognostic factors for patients unlikely to receive chemotherapy as well as those for each line of chemotherapy. First, older age, poorer PS, more severe or multiple comorbidities, more severe anemia, greater heterogeneity in erythrocyte size, and hyponatremia at diagnosis were prognostic factors of patients unlikely to receive chemotherapy. An Italian survey study showed that only 8.6% (N=85) of all patients with stage IIIB or IV NSCLC had received BSC alone, that the most frequent reasons for patient exclusion from first-line chemotherapy were poor PS (31%), older age (16%), and comorbidities (9%), and that sex, smoking habits, histological type, and disease stage did not influence decision-making regarding active treatment vs BSC alone.[@b8-lctt-7-099]

Our study additionally ascertained that certain laboratory data at diagnosis were predictive markers for treating with chemotherapy including hemoglobin, RDW, and serum sodium. Second, a poorer PS was a common independent prognostic factor for having a shorter OS for all lines of chemotherapy. In addition, we found the following variables as characteristic independent prognostic factors: lower absolute lymphocyte count for second-line chemotherapy, and being underweight and having lower hemoglobin level and higher LDH level for third-line chemotherapy. Although pretreatment higher neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are well-known prognostic markers of poorer prognosis for untreated patients with advanced NSCLC,[@b17-lctt-7-099]--[@b22-lctt-7-099] we suggest that for second-line chemotherapy, these cell counts or their ratios may be useful prognostic markers. For underweight patients, a trend toward worse outcomes was found when compared with normal and overweight patients.[@b23-lctt-7-099] Pretreatment low hemoglobin,[@b24-lctt-7-099],[@b25-lctt-7-099] increased RDW,[@b4-lctt-7-099] and high LDH[@b26-lctt-7-099],[@b27-lctt-7-099] levels have also been shown to be independent poor prognostic indicators. All the studies collected potential marker data at the time of diagnosis or before first-line chemotherapy. Regarding pretreated patients with small-cell lung cancer, higher BMI, lower levels of LDH, and higher levels of hemoglobin were prognostic markers of longer OS for third-line chemotherapy.[@b28-lctt-7-099] Thus, for third-line chemotherapy for squamous cell carcinomas, we detected four physical or laboratory test-derived prognostic factors associated with survival.

Of note, RR, DCR, and median PFS and OS decreased from 42.7%, 64.1%, and 134 and 381 days with first-line chemotherapy to 6.3%, 44.4%, and 90 and 205 days with second-line and to 3.1%, 28.1%, and 56 and 167 days with third-line chemotherapy, respectively. In previous studies, RR, DCR, and OS varied between 33%--44%, 50%--64.8%, and 7.6--15.3 months with first-line chemotherapy compared with 10.4%--23.5%, 30%--46.5%, and 4.6--12.8 months with second-line, and 6%--20%, 29.4%--60%, and 3.8--12.0 months with third-line chemotherapy, respectively. Our RRs in the second- (6.3%) and third-line (3.1%), and DCR in the third-line chemotherapy (28.1%) were slightly lower than those in previous studies, but OS with second-and third-line chemotherapy was nearly identical to those in other studies.[@b6-lctt-7-099],[@b7-lctt-7-099],[@b12-lctt-7-099]--[@b14-lctt-7-099] Our efficacies and survival rates were lower and shorter than those from a Japanese cancer center.[@b7-lctt-7-099]

Our limitations included that it was a retrospective, single-institution, and small sample-sized study. Owing to institutional bias and the small number of patients, it might be difficult to generalize our results. In addition, we did not routinely measure serum albumin levels and failed to evaluate various nutrition-based indexes. However, the predictive factors that we determined in this study are of practical relevance. Thus, our results may help oncologists faced with the dilemma of whether or not to treat with additional chemotherapy.

Conclusion
==========

In our study, \~66% of patients received chemotherapy. Of these, 66% and 33% proceeded to receive second- and third-line chemotherapy, respectively. ECOG-PS is always an essential marker when considering treating patients with chemotherapy and whether additional chemotherapy is warranted. Other markers, such as lymphocyte count, BMI, anemia, and LDH level, may be useful depending on the patient's situation, in determining whether to treat with additional chemotherapy.

Supplementary materials
=======================

###### 

Patient flowchart.

**Abbreviations:** PD, progressive disease; SQ, squamous cell carcinoma; w/o, without.

###### 

Laboratory data at diagnosis

  Variables[a](#tfn29-lctt-7-099){ref-type="table-fn"}   Chemotherapy   Non-chemotherapy   *P*[b](#tfn30-lctt-7-099){ref-type="table-fn"}
  ------------------------------------------------------ -------------- ------------------ ------------------------------------------------
  N                                                      103            51                 
  Leukocyte (cells/μL)                                   9,050±2,780    8,298±2,988        0.13
  Neutrophil (cells/μL)                                  6,453±2,531    6,108±2,788        0.44
  Lymphocyte (cells/μL)                                  1,803±697      1,478±566          \<0.01
  Monocyte (cells/μL)                                    532±221        500±219            0.40
  Hemoglobin (g/dL)                                      13.0±1.7       11.8±1.5           \<0.01
  Red cell distribution width (%)                        13.5±0.9       14.1±1.2           \<0.01
  Platelet (×10^3^ cells/μL)                             308.0±285.1    266.8±118.2        0.34
  Sodium (mEq/L)                                         139.6±3.0      137.8±3.8          \<0.01
  Lactate dehydrogenase (IU/L)                           221.9±108.6    251.1±111.9        0.12
  Alkaline phosphatase (IU/L)                            272.9±89.1     270.7±132.5        0.90
  C-reactive protein (mg/dL)                             3.4±4.6        3.2±3.7            0.81

**Notes:**

At the nearest data before diagnostic examination was performed.

Unpaired *t*-test. Data are presented as mean ± standard deviation.

###### 

Receiver operating characteristic curve analysis for optimal cutoff values of laboratory data at diagnosis for the introduction of chemotherapy

  Variables                                                                    Cutoff   Sensitivity   Specificity   AUC    95% CI
  ---------------------------------------------------------------------------- -------- ------------- ------------- ------ ------------
  Lymphocyte (cells/μL)                                                        1,710    0.51          0.75          0.64   0.55--0.73
  Hemoglobin (g/dL)[a](#tfn31-lctt-7-099){ref-type="table-fn"}                 12.2     0.73          0.63          0.70   0.61--0.78
  Red cell distribution width (%)[a](#tfn31-lctt-7-099){ref-type="table-fn"}   13.9     0.79          0.53          0.67   0.58--0.77
  Sodium (mEq/L)                                                               140      0.58          0.73          0.67   0.58--0.76

**Note:**

There was a significant inverse correlation between hemoglobin and red cell distribution width (*r*=--0.31, 95% CI --0.46 to --0.17, *P*\<0.01).

**Abbreviations:** AUC, area under the curve; CI, confidence interval.

###### 

Laboratory data at the start of first- to third-line chemotherapy

  Variables[a](#tfn33-lctt-7-099){ref-type="table-fn"}   First-line    Second-line   Third-line
  ------------------------------------------------------ ------------- ------------- -------------
  N                                                      103           63            32
  Leukocyte (cells/μL)                                   8,977±3,360   7,990±3,382   8,084±2,903
  Neutrophil (cells/μL)                                  6,411±3100    5,564±3,121   5,830±2,602
  Lymphocyte (cells/μL)                                  1,670±671     1,567±585     1,407±547
  Monocyte (cells/μL)                                    583±228       570±209       499±187
  Hemoglobin (g/dL)                                      12.2±1.8      11.2±1.8      11.2±1.8
  Red cell distribution width (%)                        13.8±1.0      14.8±1.6      15.2±1.6
  Platelet (×10^3^ cells/μL)                             284.3±108.2   241.2±99.5    255.9±91.7
  Sodium (mEq/L)                                         138.5±3.5     138.9±3.1     139.1±2.4
  Lactate dehydrogenase (IU/L)                           227.6±141.2   262.9±278.3   223.4±64.0
  Alkaline phosphatase (IU/L)                            288.3±105.8   302.9±201.6   259.8±63.2
  C-reactive protein (mg/dL)                             3.8±4.4       3.5±4.1       3.0±3.2

**Notes:**

Data obtained nearest to the start of each line of chemotherapy. Data are presented as mean ± standard deviation.

###### 

Regimens

  Regimens                           First-line   Second-line   Third-line
  ---------------------------------- ------------ ------------- ------------
  N                                  103          63            32
  Platinum-based                     92           4             4
   Platinum                                                     
    Cisplatin-based                  1            0             1
    Carboplatin-based                91           4             3
   Partner agent                                                
    Paclitaxel                       52           2             2
    nab-Paclitaxel                   16           1             0
    S-1                              18           1             1
    Gemcitabine                      3            0             0
    Docetaxel                        3            0             0
    Vinorelbine                      0            0             1
  Non-platinum doublets                                         
   Docetaxel + S-1                   0            6             0
   Gemcitabine + vinorelbine         0            2             9
  Non-platinum monotherapy                                      
   Docetaxel                         0            33            6
   EGFR-TKI                          0            12            7
   S-1                               10           6             6
   Gemcitabine                       1            0             0
  Concurrent thoracic radiotherapy   8            0             1

**Note:** Data are presented as number of patients.

**Abbreviation:** EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.

###### 

Treatment response and discontinuation

  Response and discontinuation                  First-line   Second-line   Third-line
  --------------------------------------------- ------------ ------------- ------------
  Response                                                                 
   Complete response, N                         2            0             0
   Partial response, N                          42           4             1
   Stable disease, N                            22           24            8
   Progressive disease, N                       28           27            19
   Not evaluated, N                             9            8             4
   Overall response rate, %                     42.7         6.3           3.1
   Disease control rate, %                      64.1         44.4          28.1
  Reasons of discontinuation, N                                            
   Progressive disease                          34           34            17
   Completion of four to six courses            25           7             2
   Adverse effects                              18           8             1
   Patient refusals                             2            2             0
   Transfer to other hospitals                  1            0             1
   Cancer-related deteriorated condition        8            6             6
   Comorbidity-related deteriorated condition   15           5             4
   Ongoing                                      0            0             1
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###### 

Patient characteristics at diagnosis

  Variables                                                 Chemotherapy     Non-chemotherapy   *P*
  --------------------------------------------------------- ---------------- ------------------ --------------------------------------------------
  N                                                         103              51                 
  Age (years)                                                                                   
   Mean ± SD                                                69.4±8.2         77.5±7.5           \<0.01[a](#tfn1-lctt-7-099){ref-type="table-fn"}
   Median (range)                                           70 (42--86)      78 (57--94)        
  Sex, N                                                                                        
   Male/female                                              85/18            34/17              0.04[b](#tfn2-lctt-7-099){ref-type="table-fn"}
  Staging, N                                                                                    
   IIIB/IV                                                  41/62            13/38              0.11[b](#tfn2-lctt-7-099){ref-type="table-fn"}
  ECOG-PS, N[c](#tfn3-lctt-7-099){ref-type="table-fn"}                                          
   0--1/2/3/4                                               75/25/2/1        15/13/15/8         \<0.01[d](#tfn4-lctt-7-099){ref-type="table-fn"}
  BMI (kg/m^2^)[c](#tfn3-lctt-7-099){ref-type="table-fn"}                                       
   Mean ± SD                                                21.5±3.1         21.5±3.7           0.90[a](#tfn1-lctt-7-099){ref-type="table-fn"}
  Charlson comorbidity index                                                                    
   Mean ± SD                                                1.1±1.0          1.7±1.5            0.01[d](#tfn4-lctt-7-099){ref-type="table-fn"}
  OS (days)[e](#tfn5-lctt-7-099){ref-type="table-fn"}                                           
   Median (95% CI)                                          361 (287--550)   80 (47--164)       \<0.01[f](#tfn6-lctt-7-099){ref-type="table-fn"}

**Notes:**

Unpaired *t*-test.

Fisher's exact test.

At the nearest data before diagnostic examination was performed.

Mann--Whitney *U* test.

From diagnosis to death or last survival confirmation.

Log-rank test.

**Abbreviations:** BMI, body mass index; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; OS, overall survival; PS, performance status; SD, standard deviation.

###### 

Univariate and multivariate analyses of factors influencing receipt of chemotherapy

  Variables                         Univariate   Multivariate                                
  --------------------------------- ------------ -------------- -------- ------ ------------ --------
  Age (years)                                                                                
  \<75 vs ≥75                       0.23         0.10--0.49     \<0.01   0.23   0.09--0.61   \<0.01
  Sex                                                                                        
   Male vs female                   0.43         0.18--0.99     0.04     0.37   0.12--1.10   0.08
  ECOG PS                                                                                    
   0--1 vs 2--4                     0.16         0.07--0.35     \<0.01   0.18   0.07--0.48   \<0.01
  Charlson comorbidity index                                                                 
   0--1 vs ≥2                       0.29         0.11--0.73     \<0.01   0.19   0.06--0.61   \<0.01
  Lymphocyte (cells/μL)                                                                      
   ≥1,710 vs \<1,710                0.33         0.14--0.73     \<0.01   0.60   0.22--1.61   0.31
  Hemoglobin (g/dL)                                                                          
   ≥12.2 vs \<12.2                  0.23         0.10--0.49     \<0.01   0.36   0.14--0.96   0.04
  Red cell distribution width (%)                                                            
   \<13.9 vs ≥13.9                  0.30         0.14--0.64     \<0.01   0.26   0.09--0.72   \<0.01
  Sodium (mEq/L)                                                                             
   ≥140 vs \<140                    0.27         0.12--0.59     \<0.01   0.23   0.09--0.62   \<0.01

**Abbreviations:** CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; OR, odds ratio; PS, performance status.

###### 

Pretreatment characteristics of patients who received first- to third-line chemotherapy

  Variables                                                                     First-line       Second-line                                        Third-line
  ----------------------------------------------------------------------------- ---------------- -------------------------------------------------- -------------------------------------------------
  N                                                                             103              63                                                 32
  Age (years)[a](#tfn9-lctt-7-099){ref-type="table-fn"}                                                                                             
   Mean ± SD                                                                    69.5±8.2         68.5±7.2                                           68.8±7.3
   Median (range)                                                               70 (42--86)      69 (48--83)                                        69 (56--84)
  Sex                                                                                                                                               
   Male/female                                                                  85/18            55/8                                               27/5
  Staging[a](#tfn9-lctt-7-099){ref-type="table-fn"}                                                                                                 
   ≤IIIB/IV                                                                     41/62            20[b](#tfn10-lctt-7-099){ref-type="table-fn"}/43   8[c](#tfn11-lctt-7-099){ref-type="table-fn"}/24
  ECOG PS[a](#tfn9-lctt-7-099){ref-type="table-fn"}                                                                                                 
   0--1/2/3/4                                                                   73/29/1/0        38/23/2/0                                          14/17/1/0
  BMI (mg/kg[@b2-lctt-7-099])[a](#tfn9-lctt-7-099){ref-type="table-fn"}                                                                             
   Mean ± SD                                                                    21.2±3.0         21.0±2.9                                           20.4±2.9
  Progression-free survival (days)[d](#tfn12-lctt-7-099){ref-type="table-fn"}                                                                       
   Median (95% CI)                                                              134 (114--168)   90 (57--112)                                       56 (36--76)
  Overall survival (days)[d](#tfn12-lctt-7-099){ref-type="table-fn"}                                                                                
   Median (95% CI)                                                              381 (259--517)   205 (164--363)                                     167 (109--321)

**Notes:**

At the start of each line of chemotherapy.

Including two patients with stage IIB or IIIA at the start of second-line chemotherapy.

Including one patient with stage IIB at the start of third-line chemotherapy.

From initiation of first-, second-, or third-line chemotherapy.

**Abbreviations:** BMI, body mass index; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status; SD, standard deviation.

###### 

Univariate Cox hazard analysis of factors associated with overall survival after first-line chemotherapy

  Factors                                                                   Univariate   Multivariate                                
  ------------------------------------------------------------------------- ------------ -------------- -------- ------ ------------ --------
  Age (years)                                                                                                                        
   \<75 vs ≥75                                                              0.91         0.54--1.53     0.72                         
  Sex                                                                                                                                
   Male vs female                                                           0.62         0.30--1.26     0.18                         
  ECOG PS                                                                                                                            
   0--1 vs 2--4                                                             2.50         1.52--4.12     \<0.01   2.54   1.46--4.42   \<0.01
  Stage                                                                                                                              
   \<IIIB vs IV                                                             1.53         0.94--2.49     0.09     1.60   0.93--2.75   0.09
  BMI (kg/m^2^)                                                                                                                      
   ≥18.5 vs \<18.5                                                          1.35         0.75--2.44     0.31                         
  Leukocyte (×10^3^ cells/μL)                                               1.08         1.00--1.16     0.07                         
  Neutrophil (×10^3^ cells/μL)[a](#tfn15-lctt-7-099){ref-type="table-fn"}   1.11         1.02--1.20     0.01     1.04   0.93--1.15   0.50
  Lymphocyte (×10^3^ cells/μL)[a](#tfn15-lctt-7-099){ref-type="table-fn"}   0.61         0.40--0.92     0.02     0.67   0.42--1.07   0.09
  Monocyte (×10^2^ cells/μL)[a](#tfn15-lctt-7-099){ref-type="table-fn"}     1.18         1.06--1.32     \<0.01   1.14   0.98--1.33   0.09
  Hemoglobin (mg/dL)                                                        0.88         0.75--1.03     0.10     0.90   0.74--1.10   0.31
  Red cell distribution width (%)                                           1.02         0.83--1.25     0.87                         
  Platelet (×10^5^ cells/μL)                                                1.23         1.01--1.61     0.04     0.92   0.68--1.24   0.57
  Serum sodium (mEq/L)                                                      0.96         0.91--1.02     0.21                         
  LDH (×10^2^ IU/L)                                                         1.07         0.93--1.24     0.35                         
  ALP (×10^2^ IU/L)                                                         1.41         1.10--1.81     \<0.01   1.12   0.84--1.48   0.45
  CRP (mg/dL)                                                               1.11         1.05--1.17     \<0.01   1.03   0.95--1.13   0.45

**Notes:** Coded as 1 (age ≥75 years, female, ECOG PS 2--4, stage IV, BMI \<18.5 kg/m^2^) and as 0 (age \<75 years, male, ECOG PS 0--1, stage I--III, BMI ≥18.5 kg/m^2^).

There was a significant correlation between neutrophil and monocyte counts (*r*=0.56, 95% CI 0.41--0.68, *P*\<0.01), while no significant correlation was found between neutrophil and lymphocyte counts (*r*=0.02, 95% CI --0.17 to 0.22, *P*=0.81) and between lymphocyte and monocyte counts (*r*=0.12, 95% CI --0.08 to 0.31, *P*=0.23).

**Abbreviations:** ALP, alkaline phosphatase; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; PS, performance status.

###### 

Univariate Cox hazard analysis of factors associated with overall survival after second-line chemotherapy

  Factors                                                                                                    Univariate   Multivariate                                
  ---------------------------------------------------------------------------------------------------------- ------------ -------------- -------- ------ ------------ ------
  Age (years)                                                                                                                                                         
   \<75 vs ≥75                                                                                               0.91         0.48--1.72     0.77                         
  Sex                                                                                                                                                                 
   Male vs female                                                                                            0.57         0.22--1.47     0.25                         
  ECOG PS                                                                                                                                                             
   0--1 vs 2--4                                                                                              3.11         1.66--5.83     \<0.01   2.12   1.02--4.41   0.04
  Stage                                                                                                                                                               
   \<IIIB vs IV                                                                                              2.04         1.07--3.89     0.03     1.25   0.60--2.63   0.55
  BMI (kg/m^2^)                                                                                                                                                       
   ≥18.5 vs \<18.5                                                                                           1.48         0.78--2.82     0.23                         
  Leukocyte (×10^3^ cells/μL)                                                                                1.08         1.00--1.16     0.05                         
  Neutrophil (×10^3^ cells/μL)[a](#tfn18-lctt-7-099){ref-type="table-fn"}                                    1.11         1.03--1.19     \<0.01   1.08   0.94--1.23   0.27
  Lymphocyte (×10^3^ cells/μL)[a](#tfn18-lctt-7-099){ref-type="table-fn"}                                    0.49         0.29--0.85     0.01     0.45   0.22--0.92   0.03
  Monocyte (×10^2^ cells/μL)                                                                                 1.10         0.98--1.23     0.12                         
  Hemoglobin (mg/dL)[b](#tfn19-lctt-7-099){ref-type="table-fn"}                                              0.76         0.65--0.89     \<0.01   0.92   0.75--1.12   0.39
  Red cell distribution width (%)[b](#tfn19-lctt-7-099){ref-type="table-fn"}                                 1.34         1.15--1.62     \<0.01   1.17   0.91--1.50   0.22
  Platelet (×10^5^ cells/μL)                                                                                 1.16         0.81--1.66     0.41                         
  Serum sodium (mEq/L)                                                                                       0.89         0.82--0.98     0.01     0.93   0.84--1.04   0.22
  LDH (×10^2^ IU/L)                                                                                          1.10         1.01--1.19     0.03     1.05   0.87--1.25   0.63
  ALP (×10^2^ IU/L)                                                                                          1.18         1.02--1.36     0.02     1.10   0.81--1.50   0.54
  CRP (mg/dL)                                                                                                1.11         1.03--1.18     \<0.01   1.00   0.91--1.11   0.94
  Interval between first- and second-line chemotherapy (months)[c](#tfn20-lctt-7-099){ref-type="table-fn"}   0.88         0.80--0.95     \<0.01   0.94   0.86--1.0.   0.17

**Notes:** Coded as 1 (age ≥75 years, female, ECOG PS 2--4, stage IV, BMI \<18.5 kg/m^2^) and as 0 (age \<75 years, male, ECOG PS 0--1, stage I--III, BMI ≥18.5 kg/m^2^).

No significant correlation was found between neutrophil and lymphocyte counts (*r*=0.09, 95% CI --0.16 to 0.33, *P*=0.48).

There was a significant inverse correlation between hemoglobin and red cell distribution width (*r*=−0.33, 95% CI --0.53 to --0.09, *P*\<0.01).

From the start of first-line chemotherapy to the start of second-line chemotherapy.

**Abbreviations:** ALP, alkaline phosphatase; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; PS, performance status.

###### 

Univariate Cox hazard analysis of factors associated with overall survival after third-line chemotherapy

  Factors                                                                                                    Univariate   Multivariate                                
  ---------------------------------------------------------------------------------------------------------- ------------ -------------- -------- ------ ------------ --------
  Age (years)                                                                                                                                                         
   \<75 vs ≥75                                                                                               0.96         0.40--2.32     0.93                         
  Sex                                                                                                                                                                 
   Male vs female                                                                                            0.64         0.19--2.19     0.48                         
  ECOG PS                                                                                                                                                             
   0--1 vs 2--4                                                                                              4.86         1.84--12.8     \<0.01   9.48   2.68--33.6   \<0.01
  Stage                                                                                                                                                               
   \<IIIB vs IV                                                                                              2.16         0.74--6.30     0.16                         
  BMI (kg/m^2^)                                                                                                                                                       
   ≥18.5 vs \<18.5                                                                                           2.04         0.88--4.76     0.10     4.89   1.61--14.9   \<0.01
  Leukocyte (×10^3^ cells/μL)                                                                                1.10         0.94--1.30     0.24                         
  Neutrophil (×10^3^ cells/μL)                                                                               1.15         0.97--1.37     0.12                         
  Lymphocyte (×10^3^ cells/μL)                                                                               0.76         0.41--1.42     0.39                         
  Monocyte (×10^2^ cells/μL)                                                                                 1.03         0.88--1.21     0.68                         
  Hemoglobin (mg/dL)[a](#tfn23-lctt-7-099){ref-type="table-fn"}                                              0.80         0.64--1.00     0.05     0.70   0.51--0.95   0.02
  Red cell distribution width (%)[a](#tfn23-lctt-7-099){ref-type="table-fn"}                                 1.31         1.03--1.67     0.03     1.00   0.75--1.34   0.99
  Platelet (×10^5^ cells/μL)                                                                                 1.23         0.86--1.77     0.26                         
  Serum sodium (mEq/L)                                                                                       0.97         0.84--1.12     0.69                         
  LDH (×10^2^ IU/L)                                                                                          2.01         0.98--4.12     0.06     2.79   1.22--6.38   0.01
  ALP (×10^2^ IU/L)                                                                                          1.03         0.52--2.05     0.94                         
  CRP (mg/dL)                                                                                                1.05         0.95--1.15     0.37                         
  Interval between first- and third-line chemotherapy (months)[b](#tfn24-lctt-7-099){ref-type="table-fn"}    0.96         0.92--1.01     0.13                         
  Interval between second- and third-line chemotherapy (months)[c](#tfn25-lctt-7-099){ref-type="table-fn"}   0.96         0.90--1.02     0.17                         

**Notes:** Coded as 1 (age ≥75 years, female, ECOG PS 2--4, stage IV, BMI \<18.5 kg/m^2^) and as 0 (age \<75 years, male, ECOG PS 0--1, stage I--III, BMI ≥18.5 kg/m^2^).

There was a significant inverse correlation between hemoglobin and red cell distribution width (*r*=−0.51, 95% CI −0.73 to −0.20, *P*\<0.01).

From the start of first-line chemotherapy to the start of third-line chemotherapy.

From the start of second-line chemotherapy to the start of third-line chemotherapy.

**Abbreviations:** ALP, alkaline phosphatase; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; PS, performance status.

###### 

Review of previous studies following first- to third-line chemotherapy for patients with advanced non-small-cell lung cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                  Country       Patients                                                   Study design                                                   Study periods                                               Chemotherapy                        
  -------------------------------------- ------------- ---------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------- ----------------- ----------------- -----------------
  Murillo and Koeller[@b9-lctt-7-099]    USA           NSCLC, stage IIIB--IV                                      Ten community oncology clinics, retro, cross-sectional         2000--2003                                                  417               232 (56%)         110 (28%)

  Girard et al[@b10-lctt-7-099]          France        NSCLC, stage IIIB--IV                                      A university hospital, single institution, retro               January 2000--December 2006, followed until December 2008   613               338 (55%)         173 (28%)\
                                                                                                                                                                                                                                                                                 \
                                                                                                                                                                                                                                                                                 RR 6%\
                                                                                                                                                                                                                                                                                 DCR 36%\
                                                                                                                                                                                                                                                                                 mOS 5.8 months

  Park et al[@b11-lctt-7-099]            South Korea   NSCLC, stage IIIB--IV (including 26.8% SQ)                 A university hospital, single institution, retro               March 2003--February 2007                                   82                49 (59.8%)        33 (40.2%)

  Zietemann and Duell[@b14-lctt-7-099]   Germany       NSCLC, stage IIIB wet--IV (including 27% SQ)               A hospital for chest disease, single institution, pros         January 2003--July 2007, followed until August 2010         406\              213 (52%)\        110 (27%)\
                                                                                                                                                                                                                                             \                 \                 \
                                                                                                                                                                                                                                             RR 33%\           RR 13%\           RR 8%\
                                                                                                                                                                                                                                             \                 \                 \
                                                                                                                                                                                                                                             DCR 64%\          DCR 41%\          DCR 39%\
                                                                                                                                                                                                                                             mPFS 146 days\    mPFS 49 days\     mPFS 51 days\
                                                                                                                                                                                                                                             mOS 268 days      mOS 139 days      mOS 115 days

  Gridelli et al[@b8-lctt-7-099]         Italy         NSCLC, stage IIIB--IV (including 28% SQ)                   74 multicentered, 1-year longitudinal observation, pros        January 2007--March 2008                                    790\              275 (35%)         58 (7.3%)
                                                                                                                                                                                                                                             mOS 9.1 months                      

  Younes et al[@b13-lctt-7-099]          Brazil        Stage IV NSCLC SQ 30.5%                                    Two hospitals, retro                                           1990--2008                                                  57.9%\            23.4%\            8%\
                                                                                                                                                                                                                                             RR 38.7%\         RR 10.4%\         RR 7%\
                                                                                                                                                                                                                                             DCR 50%\          DCR 30%           DCR 29.4%
                                                                                                                                                                                                                                             mOS 8 months                        

  Eccles et al[@b12-lctt-7-099]          UK            NSCLC, stage IIIB--IV (including 28% SQ)                   Two hospitals, retro                                           January 2007--December 2008, followed until March 2010      110\              50 (45%)\         10 (9%)\
                                                                                                                                                                                                                                             RR 44%\           RR 12%\           RR 20%\
                                                                                                                                                                                                                                             DCR 58%\          DCR 38%\          DCR 60%\
                                                                                                                                                                                                                                             TTP 5 months      TTP 3 months      TTP 3.75 months

  Asahina et al[@b7-lctt-7-099]          Japan         NSCLC, stage IIB, IV, and recurrent (including 14.4% SQ)   A cancer center, single institution, retro                     July 2002--June 2006                                        599\              415 (69.3%)\      230 (38.4%)\
                                                                                                                                                                                                                                             RR 35.7%\         RR 23.5%\         RR 17.0%\
                                                                                                                                                                                                                                             DCR 64.8%\        DCR 44.4%\        DCR 34.4%\
                                                                                                                                                                                                                                             mOS 15.3 months   mOS 12.8 months   mOS 12.0 months

  Reinmuth et al[@b6-lctt-7-099]         Germany       NSCLC, stage IV (including 15.9% SQ)                       A university hospital, single institution, retro               January 2004--December 2006, followed until December 2011   352\              183 (52%)\        97 (27.6%)\
                                                                                                                                                                                                                                             RR 30.7%\         RR 14.8%\         RR 12.4%\
                                                                                                                                                                                                                                             DCR 59.7%\        DCR 46.5%\        DCR 36.1%\
                                                                                                                                                                                                                                             mOS 7.6 months    mOS 6.2 months    mOS 5.2 months

  Moldvay et al[@b15-lctt-7-099]         Hungary       Lung cancer                                                Based on national inpatient and prescription database, retro   January 2008--December 2010                                 12,326            3,791 (31%)       1,174 (10%)

  Davis et al[@b2-lctt-7-099]            USA           SQ, stage IV                                               Based on Medicare database, retro                              January 2001--December 2009                                 7,029             3,405 (48%)       1,713 (24%)

  Our study                              Japan         SQ, stage IIIB and IV                                      An acute-care hospital, single institution, retro              June 2007--March 2015, followed until November 2015         103\              63 (65%)\         32 (34%)\
                                                                                                                                                                                                                                             RR 42.7%\         RR 6.3%\          RR 3.1%\
                                                                                                                                                                                                                                             DCR 64.1%\        DCR 44.4%\        DCR 28.1%\
                                                                                                                                                                                                                                             mPFS 134 days\    mPFS 90 days\     mPFS 56 days\
                                                                                                                                                                                                                                             mOS 381 days      mOS 205 days      mOS 167 days
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Percentage of patients receiving second- and third-line chemotherapy among patients receiving first-line chemotherapy.

**Abbreviations:** DCR, disease control rate; mOS, median overall survival; mPFS, median progression-free survival; NSCLC, non-small-cell lung cancer; pros, prospective study; retro, retrospective study; RR, response rate; SQ, squamous cell carcinoma; TTP, median time to progression.
